Can a Renal Angiomyolipoma Turn Into Kidney Cancer?

No. A classic renal angiomyolipoma (AML) is a benign (non-cancerous) tumor made up of blood vessels, muscle, and fat. A classic AML is not kidney cancer and is not known to “turn into” or transform into kidney cancer ^[1].

However, it is completely normal to feel anxious about a tumor in your kidney. Worries about cancer usually stem from two distinct issues: diagnostic uncertainty on imaging scans, and a separate, very rare subtype of the condition called epithelioid AML.

When Imaging Is Uncertain: The “Look-Alike” Problem

Often, an AML is diagnosed based on a CT or MRI scan rather than a tissue biopsy. The most reliable imaging clue for a classic AML is the presence of macroscopic fat (visible, distinct areas of fat) ^[2]. Kidney cancers rarely contain macroscopic fat, so when a radiologist sees it, it strongly supports the diagnosis of a benign AML ^[2].

However, about 4-5% of AMLs are fat-poor or minimal-fat, meaning they do not have enough visible fat to be easily identified ^[3]. These fat-poor AMLs can look remarkably similar to certain types of kidney cancer, particularly clear cell renal cell carcinoma (ccRCC) ^[3][4].

• It’s not transformation: If a suspected fat-poor AML is later removed and found to be kidney cancer, it did not “turn into” cancer. It was simply a cancer that was mimicking an AML on the original scan ^[3].
• The role of biopsy: When an MRI or CT scan cannot confidently distinguish a fat-poor AML from kidney cancer, your doctor may recommend a percutaneous renal mass biopsy (using a needle to take a small tissue sample) ^[5][6]. A biopsy may provide important diagnostic information, but it is not always conclusive due to the possibility of missing the most abnormal part of the tumor (sampling error) ^[5].

Note: Having a “fat-poor” tumor on an imaging scan does not automatically mean you have the rare epithelioid subtype (eAML) or cancer. It just means the scan alone cannot give a certain answer ^[3][7].

A Separate Rare Subtype: Epithelioid AML (eAML)

While classic AML is benign, there is a distinct, rare subtype called epithelioid angiomyolipoma (eAML). A classic AML does not turn into an eAML; eAML is a different type of tumor primarily made up of epithelioid cells ^[7][8].

Unlike classic AML, eAML has the potential to behave aggressively and can, in a minority of cases, spread (metastasize) like a cancer ^[9]. If an eAML is surgically removed, pathologists will examine the tissue under a microscope for specific “adverse features” that indicate a higher risk of malignant behavior. These include:

• Mitotic activity: A high number of actively dividing cells ^[10][11].
• Necrosis: Areas of dead tissue within the tumor ^[10][11].
• Vascular invasion: Tumor cells invading nearby blood vessels ^[11].
• Atypia: Cells that look highly abnormal compared to healthy cells ^[10].

Patients who have an eAML with multiple adverse features may warrant closer, individualized long-term follow-up with a urologist or oncologist to monitor for recurrence ^[9][11]. There is no single universal scan schedule; it depends entirely on your specific pathology report and clinical history.

Next Steps and Management

Your medical team’s recommendations will depend on how confident they are in the diagnosis and the characteristics of your tumor:

• Active Surveillance for Benign AML: If imaging strongly supports a classic AML, it is generally monitored with regular ultrasound, CT, or MRI scans ^[12][13]. The traditional rule of automatically treating tumors just because they are larger than 4 cm is outdated ^[13][14]. Surveillance intervals are individualized based on tumor size, growth rate, aneurysm (ballooning blood vessel) size, kidney function, and whether you are pregnant or planning to become pregnant ^[13][14].
• Managing Indeterminate Masses: If the tumor is fat-poor or cannot be confidently distinguished from kidney cancer, management focuses on getting a diagnosis or safely removing the mass. Options may include a biopsy, specialized MRI techniques, thermal ablation, or a partial nephrectomy (surgically removing the tumor while sparing the kidney) ^[5][14].
• Treating High-Risk or Symptomatic AML: If a confirmed benign AML is causing pain, bleeding, growing rapidly, or has large aneurysms, your doctor may recommend selective arterial embolization (blocking the blood supply to the tumor to shrink it and prevent bleeding) ^[13][14].

Safety Warning: Bleeding Risk
Even benign AMLs can sometimes bleed. Seek urgent or emergency medical care if you experience sudden severe flank or abdominal pain, heavy or visible blood in your urine, fainting, marked dizziness, a rapid heartbeat, or severe weakness ^[15][16].